Intellia Therapeutics (NTLA) Downgraded by BidaskClub

Share on StockTwits

BidaskClub cut shares of Intellia Therapeutics (NASDAQ:NTLA) from a buy rating to a hold rating in a research report released on Tuesday morning, BidAskClub reports.

NTLA has been the topic of several other research reports. Evercore ISI assumed coverage on Intellia Therapeutics in a report on Thursday, April 11th. They issued an outperform rating on the stock. Chardan Capital restated a buy rating and set a $57.50 price target on shares of Intellia Therapeutics in a report on Wednesday, February 27th. Zacks Investment Research downgraded Intellia Therapeutics from a buy rating to a hold rating in a report on Tuesday, January 29th. Finally, BTIG Research initiated coverage on Intellia Therapeutics in a report on Thursday, February 7th. They set a buy rating and a $20.00 price target on the stock. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $29.08.

NTLA opened at $16.15 on Tuesday. The stock has a market capitalization of $730.38 million, a PE ratio of -8.16 and a beta of 2.95. Intellia Therapeutics has a 12 month low of $11.03 and a 12 month high of $32.95.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Wednesday, February 27th. The company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.12. The firm had revenue of $7.90 million for the quarter, compared to the consensus estimate of $9.92 million. Intellia Therapeutics had a negative return on equity of 30.59% and a negative net margin of 280.42%. The company’s quarterly revenue was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.61) earnings per share. As a group, research analysts expect that Intellia Therapeutics will post -2.47 EPS for the current year.

In other Intellia Therapeutics news, EVP Andrew Schiermeier purchased 7,500 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, March 6th. The shares were bought at an average price of $15.72 per share, for a total transaction of $117,900.00. Following the acquisition, the executive vice president now directly owns 3,250 shares in the company, valued at $51,090. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.20% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the stock. We Are One Seven LLC purchased a new position in Intellia Therapeutics during the 4th quarter valued at about $28,000. Patriot Financial Group Insurance Agency LLC boosted its position in Intellia Therapeutics by 35.8% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 5,495 shares of the company’s stock valued at $75,000 after acquiring an additional 1,450 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its position in Intellia Therapeutics by 20.0% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 5,980 shares of the company’s stock valued at $82,000 after acquiring an additional 995 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Intellia Therapeutics by 52.7% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 8,381 shares of the company’s stock valued at $110,000 after acquiring an additional 2,892 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Intellia Therapeutics during the 4th quarter valued at approximately $112,000. Institutional investors own 69.64% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Recommended Story: Technical Analysis

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Head to Head Analysis: Papa John’s Int’l  versus Wingstop
Head to Head Analysis: Papa John’s Int’l versus Wingstop
Reviewing Ingevity  & Loop Industries
Reviewing Ingevity & Loop Industries
Comparing TriCo Bancshares  and 1st Source
Comparing TriCo Bancshares and 1st Source
Peel Hunt Reiterates Buy Rating for NWF Group
Peel Hunt Reiterates Buy Rating for NWF Group
Coeur Mining Inc Expected to Earn Q3 2019 Earnings of $0.01 Per Share
Coeur Mining Inc Expected to Earn Q3 2019 Earnings of $0.01 Per Share
BlackRock  Price Target Cut to $525.00
BlackRock Price Target Cut to $525.00


 
© 2006-2019 Zolmax.